Leerink Partnrs Predicts Increased Earnings for Certara

Certara, Inc. (NASDAQ:CERT) – Equities researchers at Leerink Partnrs boosted their FY2025 earnings estimates for Certara in a research report issued to clients and investors on Monday, April 14th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $0.29 per share for the year, up from their previous estimate of $0.27. The consensus estimate for Certara’s current full-year earnings is $0.28 per share.

Several other research firms have also commented on CERT. Stephens reissued an “overweight” rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Barclays dropped their price target on Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Finally, KeyCorp upped their target price on Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.17.

Certara Stock Performance

NASDAQ:CERT opened at $14.15 on Thursday. The company has a 50-day moving average of $11.62 and a 200-day moving average of $11.46. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -70.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a twelve month low of $8.64 and a twelve month high of $17.94.

Institutional Trading of Certara

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Certara by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock valued at $132,455,000 after buying an additional 38,068 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its stake in Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock valued at $66,171,000 after acquiring an additional 3,861,674 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Certara by 13.9% in the 4th quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock valued at $48,542,000 after purchasing an additional 557,348 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Certara by 4.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company’s stock valued at $43,494,000 after purchasing an additional 182,042 shares during the period. Finally, Brown Brothers Harriman & Co. lifted its position in shares of Certara by 63.8% in the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock worth $40,668,000 after purchasing an additional 1,487,998 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.